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Introduction
According to epidemiological research, colorectal cancer 
is the second most common cancer and the second 
most common cause of death from malignant disease in 
Europe, causing approximately 400,000 deaths annually 
worldwide (1-4). The main cause of death of patients with 
colorectal cancer is liver metastases (5). It is well known 
that approximately 25% of patients with colorectal cancer 
already have liver metastases, and another 25% of patients 
develop liver metastases during follow up, usually within 
the first 2 years after the diagnosis of the primary colorectal 
tumor (6). In rectal cancer, preoperative chemoradiotherapy 
(CRT) significantly reduces the rate of local recurrence 
(5.3% vs. 14.1%), but patients who were treated with 
preoperative CRT do not appear to benefit significantly in 
terms of their long-term prognosis (66.2% vs. 67.8%) (7). 
Also, improvements in surgical technique resulted in less 
local recurrence (8). 
Currently there is no reliable method for detecting 
small, occult liver metastases. Oncologists use various 
prognostic factors in deciding on adjuvant treatment. A 
standard prognostic factor that is used routinely in selecting 
patients for adjuvant treatment is the Dukes classification 
of the primary colorectal cancer (9-11). The survival of 
patients with dukes C stage as well as one part of patients 
with dukes B stage can be improved by the application of 
adjuvant chemotherapy after potentially curative surgical 
resection (12,13). Adjuvant chemotherapy (5-fluorouracil 
with levamisole or 5-fluorouracil with folinic acid) leads to 
a 40% reduction in the rate of recurrence and metastases, 
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and 33% reduction in mortality rates of patients with Dukes 
C colon cancer (14). Despite that, approximately one third 
of patients with Dukes C colon cancer will survive 5 years 
even without adjuvant chemotherapy. On the other hand, 
approximately one third of patients with Dukes B colon 
cancer will develop recurrent disease or metastases. 
However, today there is no clear recommendation for the 
application of adjuvant chemotherapy in patients with 
colorectal cancer stage Dukes B (9). Therefore, it is obvious 
that Dukes classification is insufficient for the selection of 
patients for the application of adjuvant chemotherapy after 
potentially curative resection for colorectal cancer (9). 
Careful selection of patients is crucial to improve the 
results of chemotherapy by applying it only to patients 
with the greatest impact on survival and avoiding harmful 
effects of chemotherapy in patients with no risk off liver 
metastasis (15). Therefore, the detection of those patients with 
micrometastases that are not evident at the time of primary 
tumor treatment still represents a significant challenge (16).
Current morphological methods for diagnosing liver 
metastases from colorectal cancer obviously have the 
limitation in detecting small focal liver lesions less than a 
few millimeters in diameter (17). 
Hepatic perfusion changes in patients with liver 
metastases
It has been known for a while now, that in patients with liver 
metastasis there is an alteration of blood flow through the 
liver (18). Alterations of the hepatic flow in tumors were 
initially observed using dynamic scintigraphy. In 1983 Parkin 
et al. (19) proved that when malignant tumors are present 
the arterial hepatic flow is elevated because tumors have a 
predominantly arterial vascularity. Parkin also proposed the 
use of the hepatic perfusion index (HPI), which is increased 
in patients with liver metastases. 
Several papers consistently demonstrated that a relative 
blood flow through the common hepatic artery, expressed 
as a percentage of total hepatic blood flow is significantly 
increased in patients with hepatic metastases in comparison 
to patients without liver metastases (9,20,21). 
For a long time it has been considered that the observed 
change of blood flow through the liver is exclusively the 
consequence of increased neovascularization within the 
metastases themselves. Clinical and experimental studies 
demonstrated that liver metastases from colorectal cancer 
establish their blood supply mostly through hepatic artery 
system (22-24). 
Although some research demonstrated that liver 
micrometastases indeed do derive some of their blood 
flow through the portal system, portal vascularization of 
liver metastasis is generally considered insignificant in 
comparison to vascularization derived through hepatic 
artery, especially considering the fact that the with the 
growth of metastasis there is also an increase in arterial 
blood supply compared to a portal blood supply (23). 
In spite of the well-known thinking that only metastasis 
greater than one millimeter in diameter receive their 
blood supply through newly formed blood vessels (22), 
it has been demonstrated that even metastasis with only 
half a millimeter have a defined vascularization derived 
predominantly through the system of hepatic artery (23,25). 
Hepatic neovascularization is a complex process during 
which the relative contribution of arterial and portal 
blood flow changes during the growth of liver metastases 
(24,25). In the earliest stage, liver metastasis depend on 
perfusion from adjacent issue, until they reach a diameter 
of approximately 150-200 μm (26). Further growth of the 
metastasis induces new vessel formation derived from those 
arterial and portal system. As liver metastasis increases to 
over two millimeters in size, arterial blood flow becomes 
dominant (27). Angiographic research demonstrated a great 
variability in the vascularization of liver metastasis. Some 
metastasis demonstrate minimal accumulation of contrast 
(hypovascularized metastases), while others are extremely 
well vascularized with a marked arterial supply of the entire 
liver lobe (24). These variations in blood supply of liver 
metastasis play a significant role in the choice and success 
of local therapeutic procedures such as locoregional arterial 
chemotherapy, dearterialization and embolisation. 
Doppler perfusion index (DPI)
This well known change in liver perfusion in patients 
with liver metastasis was further investigated by Leen and 
colleagues using Doppler ultrasound. In a series of papers 
he demonstrated that a Doppler ultrasound is a simple, 
non-invasive and reliable method in detecting changes in 
liver perfusion, especially in patients with colorectal cancer 
liver metastases (9,28-30). 
Some research demonstrated that DPI enables greater 
precision to determine the likelihood of the existence of 
occult metastases in the liver. The analysis of preoperative 
values of DPI on a sample of 120 patients with colorectal 
cancer confirmed the statistically significant predictive value 
of DPI the detection of liver metastasis. The sensitivity, 
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specificity, positive and negative predictive values as well as 
the accuracy of determining DPI for identification of patients 
in whom liver metastasis will be diagnosed during follow up 
was found to be 95%, 69%, 73%, 94% and 81% (9). 
Five-year follow-up of patients with colorectal cancer 
demonstrated that the blood flow redistribution through the 
liver is strongly correlated to the survival (9). In a prospective 
study, the 5-year follow-up of patients who underwent 
potentially curative resection of primary colorectal cancer 
found that patients with normal values of DPI (DPI <30%) 
had a 5-year rate of disease free survival of 89%, while the 
5-year disease free survival was only 22% in patients with 
elevated DPI (DPI ≥30%). Overall survival of patients with 
normal values of DPI was as high as 91% and only 29% in 
patients with abnormally elevated DPI (9). 
Measurement of blood flow through blood vessels 
by color Doppler is extremely dependent on a number 
of technical parameters, and even small errors in the 
measurement of the diameter or cross-sectional area of 
blood vessels or the angle at which the measurements were 
performed can produce large errors in the calculation of the 
blood flow through (Table 1) (31,32). Therefore, in most 
Table 1 Doppler perfusion index—how to do it 
Procedure How to do it
Prepare the patient Overnight fasting; supine position
Measure the diameter of the common 
hepatic artery (AHC)
In transverse plane, find the celiac trunk and locate the common hepatic artery. Set the 
size of the Doppler window to encompass AHC. Set the measurement point so that the 
Doppler axis is as close as small as possible (should not be greater than 60 degrees to 
minimize error). Measure the diameter (in centimeters) of the common hepatic artery 
perpendicular to the longitudinal axis at the selected measurement point
Measure the cross sectional area of the 
common hepatic artery
Use built-in algorithm or calculate from the diameter of the AHC:  
cross sectional area (S) =
Measure the velocity of blood flow in the 
common hepatic artery
At the same measurement point, position the Doppler cursor in the middle of the artery 
and record Doppler waves for at least 3 cardiac cycles (more cycles may be required if 
patient has arrhythmia). For each cycle determine the peak systolic velocity (PSV), end-
diastolic velocity (EDV) and mean velocity (MV) in centimeters per second. Calculate 
mean PSV, EDV and MV across several cycles
Calculate resistance index (RI) RI =
Calculate blood flow in the common 
hepatic artery (fAHC)
Use built-in algorithm or calculate blood flow in mL/s: fAHC = MV*S
Measure the diameter of the portal vein 
(PV)
Locate the portal vein before its bifurcation (adjacent to common hepatic duct). Set the 
size of the Doppler window to encompass PV. Set the measurement point so that the 
Doppler axis is as close as small as possible (should not be greater than 60 degrees to 
minimize error). Measure the diameter (in centimeters) of the portal vein perpendicular 
to the longitudinal axis at the selected measurement point
Measure the cross sectional area of the 
portal vein
Use built-in algorithm or calculate from the diameter of the PV:  
cross sectional area (S) = 
Measure the velocity of blood flow in the 
portal vein
At the same measurement point, position the Doppler cursor in the middle of the 
portal vein and record Doppler waves for at least 3 cardiac cycles (more cycles may be 
required if patient has arrhythmia). For each cycle determine the mean velocity (MV) in 
centimeters per second. Calculate mean MV across several cycles (modern ultrasound 
machines will do that automatically)
Calculate blood flow in the portal vein 
(fPV)
Use built-in algorithm or calculate blood flow in mL/s: fPV = MV × S
Calculate Doppler perfusion index (DPI) DPI =
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clinical studies where Doppler measurements were used 
to measure blood flow, mean values of several consecutive 
measurements of diameters or cross sectional areas of 
blood vessels were used to reduce the risk of errors in 
measurements (9). Analyzing the maximum speed of blood 
flow through the vessel in systole [peak systolic velocity 
(PSV)], the speed of blood flow at the end of diastole [end-
diastolic velocity (EDV)] and calculating the resistance 
index (RI) can more precisely describe the hemodynamic 
status of the arteries than the calculation of blood flow 
volume, because the calculation of the above parameters 
does not necessitate to knowledge the cross-sectional 
surface of measured vessels.
Despite the fact that ultrasonic Doppler technique is 
dependent on the examiner, technically challenging and 
often requires significant time to perform, it has confirmed 
good reproducibility and validity of the measurements 
among multiple examiners (33,34). 
Moreover, satisfactory accuracy and reproducibility 
of measurements of the DPI of the liver was found when 
the measurements were performed by operators with no 
classical medical education and after only a few months of 
training in this specific area (18). 
In spite of the standardization of measurements, values 
of blood flow often demonstrate wide dispersion (6). In 
order to maximize the extent of comparability and reduce 
the scattering of value, the flow can be expressed in relation 
to body surface area. 
In histological examinations, the diameter of coronary 
arteries has been brought in correlation with age and body 
surface area off young healthy people (35). Body surface 
area is also used as a method of standardization of the cross 
sectional area of different arteries (36). Body surface area is 
routinely used in research of blood flow through different 
vessels as well as for liver haemodynamics (37). Therefore, 
utilizing body surface area and expressing the blood flow 
through different vessels relative to body surface area is a 
specially suitable to compare vascular parameters between 
groups with substantial morphological differences (38). Also, 
body surface area is used to achieve greater comparability 
of masses of different organs, such as liver, which mass, 
expressed relatively according to body surface area can be 
used in different researches (39). There are several formulas 
that enable the calculation of the body surface area, such as 
those recommended by Mosteller or DuBois and DuBois 
(Table 2) (40,43,44). The calculation of body surface area is a 
common procedure in many clinical and scientific branches 
of medicine (45), but surprisingly in most research this 
method of standardization was not used (6). 
Another possible downfall of determining DPI with 
the purpose of detection of micrometastasis in the liver 
in patients with colorectal cancer is the factor that DPI 
is increased in patients with cirrhotic liver. However, 
hemodynamic examination of  hepatic  blood f low 
demonstrated that in patients with liver cirrhosis there is 
also an increase in liver congestion index, defined as the 
ratio of the cross sectional area of the portal vein and portal 
mean blood flow velocity (30).
However, not all authors were able to prove the clinical 
usefulness off DPI measurement in the detection of liver 
metastasis. In a clinical study conducted by Roumen 
et al. (46), 133 patients with different stages of colorectal 
cancer were examined. Reliable DPI measurements were not 
possible in 29 patients, mostly due to technical difficulties 
caused by the presence of air or other contrast media, 
obesity, scars or other reasons. In their study, they were 
unable to detect a single cut-off value that could reliably 
discriminate patients with liver metastases. It has to be noted 
that in this study no preselection of patients was performed 
and the focus was placed on the clinical usefulness of 
Doppler measurements in unselected population of patients. 
Apart from technical difficulties, Doppler perfusion 
measurements are characterized by high variability, 
which has been reported to be as high as 26% (46). 
Especially important it is the intraobserver variability that is 
not merely the result of the method or technique but rather 
a consequence of inherent subject variations.
As the Doppler measurements may well prove not to be 
Table 2 The equations that may be used for calculating body surface area in order to standardize blood flow
Author Formula
Du Bois and Du Bois (40) BSA = 0.007184 × H0.725 × W0.425
Gehan and George (41) BSA = 0.0235 × H0.42246 × W0.51456
Haycock (42) BSA = 0.024265 × H0.3964 × W0.5378
Mosteller (43) BSA = Square root [(H × W)/3,600]
H, height (cm); W, weight (kg); BSA, body surface area (m2).
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useful in everyday practice, the underlying hypothesis of 
the existence of a humoral vasoactive substance responsible 
for hepatic perfusion changes sheds the new light on the 
clinical and preclinical research directed towards finding an 
easily and reliably measured systemic factor.
Possibility of a humoral vasoactive factor
Until now, the cause of this redistribution of hepatic blood 
flow is not clearly explained. According to one hypothesis, 
this phenomenon is caused by splanchnic vasoconstriction 
and a consequent reduction of portal blood flow with a 
simultaneous increase in common hepatic artery flow 
as a result of hemodynamic compensation (15). Some 
experimental and clinical research indeed demonstrated 
that in patients with liver metastases that are too small to 
be detected by conventional radiologic methods there is 
already an alteration in the blood flow through the liver that 
was shown to be highly sensitive in the detection of small, 
occult liver metastasis (9,18,20,47). This raises the question 
on the nature of these haemodynamic changes, since these 
small, occult metastases are unlikely to be the cause of 
sufficient neovascularization responsible for significant 
changes in hepatic perfusion (Table 3). It was therefore 
hypothesized that the primary cause of hepatic perfusion 
changes in patients with colorectal cancer liver metastases is 
a circulating vazoactive factor causing primarily splanchnic 
vasoconstriction and subsequent reduction in portal inflow 
to the liver. 
In order to prove the hypothesis of circulating vasoactive 
factor as a possible cause of liver hemodynamic changes in 
patients with colorectal cancer and liver metastasis, a group 
of researchers conducted a research on animal model (49). In 
this research, isolated intestinal loop of a healthy animal was 
perfused with blood from another animal with experimentally 
induced liver sarcoma (HSN sarcoma) (49). 
The experiment showed that splanchnic vascular 
resistance in healthy animals was significantly greater during 
perfusion with blood from tumor bearing animals [91.6 
(SE 21.5), vs. 51.7 (SE 7.41), P=0.036]. The results of this 
experiment suggest that observed hemodynamic changes 
are at least partly mediated by a circulating agent. Whether 
this circulating agent is produced by the tumor itself or is 
an endogenous agent remains unclear (49). 
In another animal experiment (47), liver metastases 
were induced in 30 male Wistar rats by inoculating Walker 
256 tumor subcutaneously. Hemodynamic changes were 
observed and correlated to the liver histology at the time of 
measurement. By measuring the flow through the hepatic 
artery and portal vein in this animal model of spontaneous 
liver metastases, Yarmenitis and colleagues have shown 
a statistically significant increase in blood flow through 
the common hepatic artery as early as the fourth day after 
implantation of the primary tumor, when histological 
examination of the liver demonstrated only single tumor 
cells or small clusters in the connective tissue of porta 
hepatis and periportal interlobular space (47). 
DPI values were significantly increased as early as on 
the fourth day after implantation of the primary tumor, 
and did not significantly increase until the fifteenth day, 
when the histological examination showed metastatic 
tumors in the liver with the largest diameter of 2 mm. Also, 
the flow through the portal vein was reduced in animals 
with metastatic tumors in the liver on the fourth day, but 
the difference was not statistically significant. Therefore, 
a statistically significant increase in DPI and blood flow 
through the hepatic artery was observed only four days 
after implantation of tumor cells, when the histological 
analysis of the liver in these animals was not able to 
demonstrate any vascular component of either the hepatic 
artery or portal vein.
This finding is consistent with the hypothesis of the 
existence of a humoral vasoactive factor that can lead to 
hemodynamic changes in the liver in the earliest stages 
of the development of metastases, and that its effect 
may manifest both locally, in the liver, as well as in the 
splanchnic circulation away from metastases (49). Opposite 
to some other studies (48,49), in the experimental study 
conducted by Yarmenitis and associates, DPI changes were 
primarily attributed to a statistically significant increase in 
Table 3 Possible etiology of change in flow
Main proposed etiology Studies
Increased hepatic arterial blood flow Parkin, 1983 (19); Ridge, 1987 (24); Archer, 1989 (25)
Decreased portal blood flow Nott, 1991 (48); Carter, 1994 (49); Yarmenitis, 2000 (47)
Decreased portal blood flow with compensatory increase in 
hepatic arterial blood flow
Kopljar, 2004 (6)
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the flow through the hepatic artery and without significant 
changes in portal flow (47).
In the research conducted by Nott and coworkers (48), 
the blood flow through the portal vein was significantly 
reduced in animals with experimentally induced sarcoma 
of the liver (Walker carcinosarcoma). The results of this 
study indicate that overt tumor derived from the intraportal 
inoculation of Walker cells results in an increase in the HPI. 
The blood supply to the tumor was shown to be derived 
principally from the hepatic artery. However, hepatic 
arterial flow did not change in the presence of tumor and 
the alterations in the HPI were found to be secondary to a 
reduction in portal venous inflow. Moreover, the presence of 
overt hepatic tumor was associated with gross derangement 
of hepatic hemodynamic with a pronounced increase in 
intrahepatic arteriovenous shunting. It was concluded that 
hemodynamic changes accompanying the development of 
overt hepatic tumor are complex and must be taken into 
account when attempting to potentiate the distribution 
of cytotoxics to the tumor by regional administration or 
through manipulation of liver blood flow (48).
Other researchers also demonstrated significant 
reduction of portal flow in experimental models of liver 
metastasis, with no changes in arterial hepatic flow (50). An 
experimental and biomolecular research identified some 
systemic active factors that might, at least in theory, explain 
the redistribution of blood flow through the liver in patients 
with colorectal liver metastasis (51). 
One possible causative agent might be endothelin-1 (15), 
a potent vasoconstrictor with significant influence on 
the portal blood flow that is regularly produced by the 
colorectal cancer. Peeters and coworkers measured the 
serum level of endothelin-1 in 68 patients with colorectal 
cancer and 20 healthy volunteers without malignant disease. 
The sera level of endothelin-1 was statistically significantly 
higher in patients with colorectal cancer compared to 
healthy participants. Further subgroup analysis was 
performed and patients were divided into three groups: 
those with primary colorectal cancer without metastasis, 
patients with colorectal cancer that developed metastasis 
during follow up and patients with colorectal cancer and 
synchronous liver metastasis. All three subgroups had 
higher concentrations of endothelin-1 compared to healthy 
participants. However, no statistically significant difference 
in preoperative concentration of endothelin-1 was found 
between healthy participants and patients with liver 
metastasis from previously resected colorectal cancer (15). 
Animal models demonstrated that endothelin-1 results 
in increased blood pressure in the portal vein (52,53). Also, 
it has been determined that endothelin-1 is synthesized and 
released from several human epithelial carcinomas. Inagaki 
and coworkers demonstrated the existence of increased 
quantities of endothelin-1 in the tissue of primary colorectal 
carcinoma (54). Furthermore, histochemical methods 
demonstrated the presence of endothelin-1 in the cytoplasm 
of colorectal cancer cells metastatic to the liver, as well 
as in cytoplasm of adjacent myofibroblasts. These results 
indicate that endothelin-1 is not produced only in tumor 
cells but also in adjacent cells, thereby influencing the 
growth of the tumor (51). Unfortunately, survival analysis 
did not demonstrate prognostic value of pre-operative 
determination of the concentration of endothelin-1 in 
patients with colorectal cancer (15). 
In one clinical study (6) results showed that the DPI 
successively increased in patients with colorectal cancer 
with no signs of liver metastases and in patients with liver 
metastases. There was a statistically significant difference 
in the blood flow through the portal vein between patients 
with colorectal cancer without signs of metastases in the 
liver and healthy control patients, but no statistically 
significant differences in the flow through the common 
hepatic artery (6). However, the flow through the common 
hepatic artery and portal vein in patients with primary 
colorectal cancer with no signs of liver metastases and 
those with liver metastases, as well as between patients with 
liver metastases and control subjects showed statistically 
significant differences in the absolute values of flow through 
common hepatic artery and portal vein as well as the values 
of the flow through the same blood vessels expressed 
relative to body surface area (6). 
These results suggest that the early hemodynamic 
changes in patients with liver metastases are associated 
with a reduction of flow through the portal vein, while the 
increase in blood flow through the common hepatic artery is 
associated with the development of tumor neovascularization 
in larger metastases (6).
Furthermore, clinical research demonstrated no 
statistically significant differences in the blood flow through 
the superior mesenteric artery between patients with liver 
metastases and those without metastases, and the difference 
in RI was marginally statistically significant (6).
These findings are certainly at least partly influenced 
by the difficulties in measuring the cross-sectional area of 
blood vessels and blood flow in general, which is why the 
measurements of vascular index have the advantage.
The hypothesis of the existence of systematic acting, 
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circulating humoral vasoactive factor in patients with liver 
metastases is further supported by the analysis results 
obtained by measuring the flow rate and RI of the superior 
mesenteric artery among the three groups of patients 
(patients with liver metastases, those with primary colorectal 
cancer and no detectable metastases and patients with no 
malignancy). If this hypothesis is correct, and if indeed a 
humoral vasoactive factors can be found in the bloodstream 
of patients with metastases in the liver, then its actions 
should be expressed also on remote vessels, outside of the 
liver. 
Indeed, the EDV in the superior mesenteric artery 
was higher in healthy subjects compared to patients 
with colorectal cancer and no signs of liver metastases as 
well as compared to patients with liver metastases, while 
the difference in end-diastolic velocity in the superior 
mesenteric artery in patients with colorectal cancer without 
signs of metastases in the liver and patients with metastases 
was not statistically significant (6). Statistically significant 
differences of RI were found among healthy subjects, 
patients with colorectal cancer without signs of metastases 
in the liver and patients with metastases (6). These results 
clearly indicate that even in patients with colorectal cancer 
without clinical and radiological signs of metastases in the 
liver, there is a systemic alteration of blood flow, which is 
reflected in the reduction of the end-diastolic velocity in the 
superior mesenteric artery.
Conclusions
In the last three decades, many clinical and preclinical 
studies demonstrated that DPI measurements may be used 
to accurately diagnose and predict liver metastases from 
primary colorectal cancer. However, Doppler measurements 
have some serious limitations when applied to general 
population. Ultrasound is very operator-dependent, and 
requires skilled examiners. Also, many conditions may 
limit the use of Doppler ultrasound and ultrasound in 
general, such as the presence of air in digestive tract, 
cardiac arrhythmias (including rather common atrial 
fibrillation), vascular anomalies (e.g., the origin of right 
hepatic artery from superior mesenteric artery), obesity and 
other conditions (6,46). Therefore, in spite of the results 
from clinical studies, its value may be limited in everyday 
practice. 
On the contrary, scientific research of the DPI in 
detection of liver metastases is of great importance, since 
current research speaks strongly for the presence of 
systemic vasoactive substance responsible for observed 
hemodynamic changes. Identification of such a systemic 
vasoactive substance may lead to the development of a 
simple and reproducible laboratory test that may reliably 
identify the presence of occult liver metastases and therefore 
increase the success of adjuvant chemotherapy through 
better selection of patients. Further research in this subject 
is therefore of great importance. 
Acknowledgements
Disclosure: The authors declare no conflict of interest.
References
1. Boyle P, Langman JS. ABC of colorectal cancer: 
Epidemiology. BMJ 2000;321:805-8.
2. Jurisić I, Paradzik MT, Jurić D, et al. National program 
of colorectal carcinoma early detection in Brod-Posavina 
County (east Croatia). Coll Antropol 2013;37:1223-7.
3. Milas J, Samardzić S, Miskulin M. Neoplasms (C00-D48) 
in Osijek-Baranja County from 2001 to 2006, Croatia. 
Coll Antropol 2013;37:1209-22.
4. Samardzić S, Mihaljević S, Dmitrović B, et al. First six 
years of implementing colorectal cancer screening in the 
Osijek-Baranja County, Croatia--can we do better? Coll 
Antropol 2013;37:913-8.
5. Doko M, Zovak M, Ledinsky M, et al. Safety of 
simultaneous resections of colorectal cancer and liver 
metastases. Coll Antropol 2000;24:381-90.
6. Kopljar M, Brkljacic B, Doko M, et al. Nature of Doppler 
perfusion index changes in patients with colorectal cancer 
liver metastases. J Ultrasound Med 2004;23:1295-300.
7. Boras Z, Kondza G, Sisljagić V, et al. Prognostic factors 
of local recurrence and survival after curative rectal cancer 
surgery: a single institution experience. Coll Antropol 
2012;36:1355-61.
8. Krebs B, Kozelj M, Potrc S. Rectal cancer treatment and 
survival--comparison of two 5-year time intervals. Coll 
Antropol 2012;36:419-23.
9. Leen E, Goldberg JA, Angerson WJ, et al. Potential role 
of doppler perfusion index in selection of patients with 
colorectal cancer for adjuvant chemotherapy. Lancet 
2000;355:34-7.
10. Cunningham D, Findlay M. The chemotherapy of 
colon cancer can no longer be ignored. Eur J Cancer 
1993;29A:2077-9.
11. Bosman FT. Prognostic value of pathological 
266 Kopljar et al. Doppler perfusion index in detection of liver metastases
© Hepatobiliary Surgery and Nutrition. All rights reserved. Hepatobiliary Surg Nutr 2014;3(5):259-267www.thehbsn.org
characteristics of colorectal cancer. Eur J Cancer 
1995;31A:1216-21.
12. Haller DG. An overview of adjuvant therapy for colorectal 
cancer. Eur J Cancer 1995;31A:1255-63.
13. van Triest B, van Groeningen CJ, Pinedo HM. Current 
chemotherapeutic possibilities in the treatment of 
colorectal cancer. Eur J Cancer 1995;31A:1193-7.
14. Moertel CG, Fleming TR, Macdonald JS, et al. 
Fluorouracil plus levamisole as effective adjuvant therapy 
after resection of stage III colon carcinoma: a final report. 
Ann Intern Med 1995;122:321-6.
15. Peeters CF, Thomas CM, Sweep FC, et al. Elevated 
serum endothelin-1 levels in patients with colorectal 
cancer; relevance for prognosis. Int J Biol Markers 
2000;15:288-93.
16. Fong Y. Doppler perfusion index in colorectal cancer. 
Lancet 2000;355:5-6.
17. Akhurst T, Kates TJ, Mazumdar M, et al. Recent 
chemotherapy reduces the sensitivity of [18F]
fluorodeoxyglucose positron emission tomography in 
the detection of colorectal metastases. J Clin Oncol 
2005;23:8713-6.
18. Leen E. The detection of occult liver metastases of 
colorectal carcinoma. J Hepatobiliary Pancreat Surg 
1999;6:7-15.
19. Parkin A, Robinson PJ, Baxter P. Liver perfusion 
scintigraphy. Method, normal range and laparotomy 
correlation in 100 patients. Nuclear Medicine 
Communications 1983;4:395-402.
20. Leen E, Angerson WJ, Wotherspoon H, et al. Detection 
of colorectal liver metastases: comparison of laparotomy, 
CT, US, and Doppler perfusion index and evaluation of 
postoperative follow-up results. Radiology 1995;195:113-6.
21. Leen E, Goldberg JA, Robertson J, et al. Early detection 
of occult colorectal hepatic metastases using duplex colour 
Doppler sonography. Br J Surg 1993;80:1249-51.
22. Ackerman NB. The blood supply in liver metastases. In: 
Weiss L, Gilbert HA. eds. Liver Metastases. Boston: Hall, 
1982:96-125.
23. Lin G, Lunderquist A, Hägerstrand I, et al. Postmortem 
examination of the blood supply and vascular pattern of 
small liver metastases in man. Surgery 1984;96:517-26.
24. Ridge JA, Bading JR, Gelbard AS, et al. Perfusion of 
colorectal hepatic metastases. Relative distribution of 
flow from the hepatic artery and portal vein. Cancer 
1987;59:1547-53.
25. Archer SG, Gray BN. Vascularization of small liver 
metastases. Br J Surg 1989;76:545-8.
26. Strohmeyer T, Haugeberg G, Lierse W. Angioarchitecture 
and blood supply of micro- and macrometastases in human 
livers. An anatomic-pathological investigation using 
injection-techniques. J Hepatol 1987;4:181-9.
27. Ackerman NB. Experimental studies on the role of the 
portal circulation in hepatic tumor vascularity. Cancer 
1986;58:1653-7.
28. Leen E, Goldberg JA, Robertson J, et al. The use of 
duplex sonography in the detection of colorectal hepatic 
metastases. Br J Cancer 1991;63:323-5.
29. Robertson J, Leen E, Goldberg JA, et al. Flow 
measurement using duplex Doppler ultrasound: 
haemodynamic changes in patients with colorectal liver 
metastases. Clin Phys Physiol Meas 1992;13:299-310.
30. Leen E, Goldberg JA, Anderson JR, et al. Hepatic 
perfusion changes in patients with liver metastases: 
comparison with those patients with cirrhosis. Gut 
1993;34:554-7.
31. Breyer B. Medicinski ultrazvuk - uvod u fiziku i tehniku. 
Zagreb: Školska knjiga; 1989. Available online: http://www.
skolskaknjiga.hr
32. Burns PN. Physics and instrumentation: doppler. In: 
Goldberg BB. eds. Textbook of abdominal ultrasound. 
Baltimore: Williams & Wilkins; 1993, 24-9. Available 
online: http://www.lww.com
33. Oppo K, Leen E, Angerson WJ, et al. Doppler perfusion 
index: an interobserver and intraobserver reproducibility 
study. Radiology 1998;208:453-7.
34. Krüger S, Strobel D, Wehler M, et al. Hepatic Doppler 
perfusion index--a sensitive screening method for detecting 
liver metastases? Ultraschall Med 2000;21:206-9.
35. Litovsky SH, Farb A, Burke AP, et al. Effect of age, 
race, body surface area, heart weight and atherosclerosis 
on coronary artery dimensions in young males. 
Atherosclerosis 1996;123:243-50.
36. Huonker M, Schmid A, Schmidt-Trucksass A, et al. Size 
and blood flow of central and peripheral arteries in highly 
trained able-bodied and disabled athletes. J Appl Physiol 
(1985) 2003;95:685-91.
37. Bombelli L, Genitoni V, Biasi S, et al. Liver hemodynamic 
flow balance by image-directed Doppler ultrasound 
evaluation in normal subjects. J Clin Ultrasound 
1991;19:257-62.
38. Zeppilli P, Vannicelli R, Santini C, et al. Echocardiographic 
size of conductance vessels in athletes and sedentary 
people. Int J Sports Med 1995;16:38-44.
39. Kuo PC, Li K, Alfrey EJ, et al. Magnetic resonance 
imaging and hepatic hemodynamics: correlation with 
267HepatoBiliary Surgery and Nutrition, Vol 3, No 5 October 2014
© Hepatobiliary Surgery and Nutrition. All rights reserved. Hepatobiliary Surg Nutr 2014;3(5):259-267www.thehbsn.org
metabolic function in liver transplantation candidates. 
Surgery 1995;117:373-9.
40. Du Bois D, Du Bois EF. A formula to estimate the 
approximate surface area if height and weight be known. 
1916. Nutrition 1989;5:303-11; discussion 312-3.
41. Gehan EA, George SL. Estimation of human body surface 
area from height and weight. Cancer Chemother Rep 
1970;54:225-35.
42. Haycock GB, Schwartz GJ, Wisotsky DH. Geometric 
method for measuring body surface area: a height-weight 
formula validated in infants, children, and adults. J Pediatr 
1978;93:62-6. 
43. Mosteller RD. Simplified calculation of body-surface area. 
N Engl J Med 1987;317:1098. 
44. Wang Y, Moss J, Thisted R. Predictors of body surface 
area. J Clin Anesth 1992;4:4-10. 
45. Favier M, de Cazanove F, Saint-Martin F, et al. Preventing 
medication errors in antineoplastic therapy. Am J Hosp 
Pharm 1994;51:832-3.
46. Roumen RM, Scheltinga MR, Slooter GD, et al. 
Doppler perfusion index fails to predict the presence of 
occult hepatic colorectal metastases. Eur J Surg Oncol 
2005;31:521-7.
47. Yarmenitis SD, Kalogeropoulou CP, Hatjikondi O, et 
al. An experimental approach of the Doppler perfusion 
index of the liver in detecting occult hepatic metastases: 
histological findings related to the hemodynamic 
measurements in Wistar rats. Eur Radiol 2000;10:417-24.
48. Nott DM, Grime SJ, Yates J, et al. Changes in hepatic 
haemodynamics in rats with overt liver tumour. Br J 
Cancer 1991;64:1088-92.
49. Carter R, Anderson JH, Cooke TG, et al. Splanchnic blood 
flow changes in the presence of hepatic tumour: evidence 
of a humoral mediator. Br J Cancer 1994;69:1025-6.
50. Hemingway DM, Cooke TG, Grime SJ, et al. Changes 
in hepatic haemodynamics and hepatic perfusion index 
during the growth and development of hypovascular HSN 
sarcoma in rats. Br J Surg 1991;78:326-30.
51. Shankar A, Loizidou M, Aliev G, et al. Raised endothelin 1 
levels in patients with colorectal liver metastases. Br J Surg 
1998;85:502-6.
52. Okumura S, Takei Y, Kawano S, et al. Vasoactive 
effect of endothelin-1 on rat liver in vivo. Hepatology 
1994;19:155-61.
53. Dugdale PE, Miles KA. Hepatic metastases: the value 
of quantitative assessment of contrast enhancement on 
computed tomography. Eur J Radiol 1999;30:206-13.
54. Inagaki H, Bishop AE, Eimoto T, et al. Autoradiographic 
localization of endothelin-1 binding sites in human colonic 
cancer tissue. J Pathol 1992;168:263-7.
Cite this article as: Kopljar M, Patrlj L, Bušić Ž, Kolovrat 
M, Rakić M, Kliček R, Židak M, Stipančić I. Potential use of 
Doppler perfusion index in detection of occult liver metastases 
from colorectal cancer. Hepatobiliary Surg Nutr 2014;3(5):259-
267. doi: 10.3978/j.issn.2304-3881.2014.09.04
